NIOX GroupCSSPF 77 3-Year EBITDA Growth Rate is 1.90% as of Dec. 2025, which is 77% below its 10-year median of 8.40. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 694 Medical Devices & Instruments companies, NIOX Group ranks worse than 61.53% on this metric.
During the past 12 months, NIOX Group's average EBITDA Per Share Growth Rate was 33.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 1.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of NIOX Group was 56.80% per year. The lowest was -49.00% per year. And the median was 8.40% per year.
NIOX Group (OTCPK:CSSPF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
NIOX Group 3-Year EBITDA Growth Rate Related Terms
CSSPF vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, NIOX Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where NIOX Group's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 1.90% mean?
NIOX Group (CSSPF) has a 3-Year EBITDA Growth Rate of 1.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NIOX Group and its competitors. This is 77% below median its historical median of 8.40. According to the industry distribution chart, NIOX Group ranks #427 out of 694 companies in the Medical Devices & Instruments industry, placing it in the top 61.5%.
Is NIOX Group's 3-Year EBITDA Growth Rate too high?
NIOX Group's current 3-Year EBITDA Growth Rate of 1.90% is 77% below median its 10-year median of 8.40. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.65. NIOX Group's value of 1.90% is 75.2% below this industry median. Based on the distribution chart, NIOX Group ranks #427 out of 694 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #427 out of 694 companies for 3-Year EBITDA Growth Rate. This places NIOX Group in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.65. NIOX Group's value of 1.90% is 75.2% below this benchmark. While the company's 10-year median is 8.40 vs. the industry median of 7.65, NIOX Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.65, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current 3-Year EBITDA Growth Rate of 1.90% is 75.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current 3-Year EBITDA Growth Rate is 1.90%, which is 77% below median its own 10-year median of 8.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 1.90%, which is 77% below median its 10-year median of 8.40 and 75.2% below the Medical Devices & Instruments industry median of 7.65. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For NIOX Group (CSSPF), the current 3-Year EBITDA Growth Rate is 1.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
3-Year EBITDA Growth Rate: 1.90% (77% below median its 10-year median of 8.40)
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 75.2% below the Medical Devices & Instruments median (#427 of 694)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 